FDA Revokes HCQ's Emergency Use Authorization For COVID-19

The US Food and Drug Administration (FDA), in a statement, said it has revoked the emergency use authorization (EUA) that allowed for chloroquine phosphate and hydroxychloroquine sulfate to be used for treatment of COVID-19 patients. The FDA said that on the basis of analysis and data, it has determined that HCQ is unlikely to be effective in treating COVID-19 for the authorized uses in the EUA. The FDA also said that with many patients suffering cardiac arrests due to HCQ, the potential benefits of HCQ no longer outweigh the risks involved.